Seed Funding

Two cartoons pushing puzzle pieces together
Investment
Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75mChroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75m

The merger and $75 million Series A financing will drive the development of epigenetic editing and in vivo delivery technologies to accelerate genetic medicines.

byMillie Nelson, Editor
Dec 23, 2024
|
1 Min Read
Obesity on a board
Investment
Antag bags $84M in series A funding to drive obesity candidate to the clinicAntag bags $84M in series A funding to drive obesity candidate to the clinic
byMillie Nelson
Dec 19, 2024
1 Min Read
Asia currency
Investment
Eyes on Asia: Sanofi expands China footprint; Takeda buys anemia assetEyes on Asia: Sanofi expands China footprint; Takeda buys anemia asset
byRichard Daverman
Dec 17, 2024
1 Min Read
plan prepare perform
Investment
‘Luck only comes to the most prepared people,’ says AltruBio CEO‘Luck only comes to the most prepared people,’ says AltruBio CEO
byMillie Nelson
Dec 13, 2024
1 Min Read
A whiteboard saying transition
Investment
From Series A to B: Navigating the transition from promise to proofFrom Series A to B: Navigating the transition from promise to proof
byMillie Nelson
Nov 20, 2024
1 Min Read
thumbnail
Seed Funding
Europe’s adversity to risk is why the US is ahead, say expertsEurope’s adversity to risk is why the US is ahead
byMillie Nelson
Nov 5, 2024
1 Min Read
VC/PE
'Is the worst behind us?' Financial expert talks biotech funding
'Is the worst behind us?' Financial expert talks biotech funding
Oct 21, 2024
|
1 Min Read
byBrian Scanlan, Dan Stanton
Dollar notes
Investment
The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B
The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B
Oct 17, 2024
|
1 Min Read
byMillie Nelson, Editor
Overhead view of business people working and funding
Investment
$325 million Series C funding in its Arsenal (Biosciences)
$325 million Series C funding in its Arsenal (Biosciences)
Sep 25, 2024
|
1 Min Read
byMillie Nelson, Editor
People making business deals
Partnering
Prometheus and Merck: Under the bonnet of the largest pre-Phase III M&A deal
Under the bonnet of the largest pre-Phase III M&A deal
Sep 25, 2024
|
1 Min Read
byMillie Nelson, Editor
Innovation
GSK, Novartis, Calliditas among winners at LSX Awards
GSK, Novartis, Calliditas among winners at LSX Awards
Nov 16, 2023
|
1 Min Read
byMillie Nelson, Editor

BIO-EUROPE COVERAGE

Novo Nordisk sign
Business Strategy
Lessons and blessings: The Novo Nordisk way
Lessons and blessings: The Novo Nordisk way
Michael May, PhD, President, CCRM discusses Canada as a place for life sciences in this video.
Hubs
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Shaking hands
Partnering
Picky pharma prone to better proven partners amid dealmaking downturn
Picky pharma prone to better proven partners amid dealmaking downturn
Hervé Ansanay, Biotech Alliance Manager, discusses the features of the RESEAU SATT - SATT NETWORK
Hubs
RESEAU SATT, the Best of French Deep Tech
RESEAU SATT, the Best of French Deep Tech
Jan 13 - Jan 15, 2025
An all-inclusive healthcare conference at Hilton Union Square, San Francisco
Register

Latest

Novo Nordisk logo on a window
Business Strategy
Novo on the ‘ins and outs’ of its nucleic acid growth
Novo on the ‘ins and outs’ of its nucleic acid growth
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM written on wooden blocks in blue
Investment
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.
Stay Updated